Ironwood Wealth Management LLC. decreased its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 31.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,621 shares of the biopharmaceutical company’s stock after selling 4,352 shares during the quarter. Ironwood Wealth Management LLC.’s holdings in Bristol-Myers Squibb were worth $400,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb during the first quarter worth approximately $27,000. Fairman Group LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $42,000. Beach Investment Counsel Inc. PA purchased a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth about $42,000. Accent Capital Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $46,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $47,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol-Myers Squibb Price Performance
NYSE:BMY opened at $52.48 on Wednesday. The business’s 50-day moving average price is $49.43 and its 200 day moving average price is $46.34. The firm has a market cap of $106.38 billion, a P/E ratio of -16.93, a PEG ratio of 12.96 and a beta of 0.46. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $57.65. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86.
Bristol-Myers Squibb Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be issued a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a yield of 4.57%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.
Analysts Set New Price Targets
A number of research analysts have issued reports on BMY shares. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 16th. TD Cowen increased their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Finally, Barclays increased their price objective on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $53.43.
Get Our Latest Stock Analysis on Bristol-Myers Squibb
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Bristol-Myers Squibb
- Business Services Stocks Investing
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What Investors Need to Know to Beat the Market
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.